Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | TLR4 | O00206 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | TYMS | P04818 | 1/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.71 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.71 |
| ▸ | GART | P22102 | 1/20 | 0.71 |
| ▸ | APEX1 | P27695 | 1/20 | 0.71 |
| ▸ | CASP1 | P29466 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22594895 | 0.92 | DHFR (0.61) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL25722178 | 0.91 | CA1 (0.70) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL4814461 | 0.90 | CA1 (0.69) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL25000315 | 0.89 | DHFR (0.57) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL20223656 | 0.89 | DHFR (0.70) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL13530089 | 0.88 | HDAC4 (0.74) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL20386837 | 0.88 | CA1 (0.63) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL20386833 | 0.88 | CA1 (0.63) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL3175498 | 0.86 | HDAC4 (0.76) | DHFRKDM4ETLR4MEN1ALDH1A1 | |
| SCHEMBL13530087 | 0.85 | CA1 (0.63) | DHFRKDM4ETLR4MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | TAMBO, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230172956-A1 | COMBINATORIAL THERAPY FOR USE IN INDUCING IMMUNOGENIC CELL DEATH IN CANCER CELLS | HARTMANN JAMES (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11583536-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220409582-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | SEALD AS (NO) | 2022-12-29 | — | — | US | disclosed |
| US-11311624-B2 | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-26 | — | — | US | disclosed |
| US-11253604-B2 | Conjugate of methotrexate and peptide | CAREGEN CO., LTD. (KR) | 2022-02-22 | — | — | US | disclosed |
| US-20210236648-A1 | CONJUGATE OF METHOTREXATE AND PEPTIDE | CAREGEN CO., LTD. (KP) | 2021-08-05 | — | — | US | disclosed |
| WO-2021080955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021080950-A1 | METHODS FOR TREATING A HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | CELGENE CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20210113576-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2021-04-22 | — | — | US | disclosed |
| US-20210116454-A1 | METHODS FOR TREATING A HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | CELGENE CORPORATION (US) | 2021-04-22 | — | — | US | disclosed |
| US-20200164081-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR AND MEK/PI3K/mTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-28 | — | — | US | disclosed |
| WO-2018136778-A1 | TELODENDRIMERS WITH RIBOFLAVIN MOIETIES AND NANOCARRIERS AND METHODS OF MAKING AND USING SAME | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2017210489-A1 | COMPOUNDS | M3 BIOTECHNOLOGY, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | YOSHIHIRO ISHIKAWA (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | ICOS, CD74, PBK | DHFR 127/4885KDM4E 4007/4885TLR4 928/4885 |
| US-20230158037-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | DHFR 4491/4885KDM4E 174/4885TLR4 3349/4885 |
| US-20210236648-A1 | CONJUGATE OF METHOTREXATE AND PEPTIDE | MTX1, MTX2, CCL2 | DHFR 4/4885KDM4E 4119/4885TLR4 732/4885 |
| US-11253604-B2 | Conjugate of methotrexate and peptide | MTX1, MTX2, CCL2 | DHFR 4/4885KDM4E 4119/4885TLR4 732/4885 |
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | SDHB, SDHA, SLC40A1 | DHFR 305/4885KDM4E 2197/4885TLR4 4055/4885 |
| US-20210113576-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | DHFR 4464/4885KDM4E 193/4885TLR4 3296/4885 |
| US-11311624-B2 | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | MTOR, JAK2, JAK1 | DHFR 1175/4885KDM4E 1270/4885TLR4 953/4885 |
| US-20220409582-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | HDAC6, HDAC3, CHKA | DHFR 1048/4885KDM4E 199/4885TLR4 4034/4885 |
| US-20210116454-A1 | METHODS FOR TREATING A HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | MYADM, MCL1, FLI1 | DHFR 302/4885KDM4E 692/4885TLR4 4465/4885 |
| US-11583536-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | DHFR 4464/4885KDM4E 193/4885TLR4 3296/4885 |
| US-20200164081-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR AND MEK/PI3K/mTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | MTOR, JAK2, JAK1 | DHFR 1175/4885KDM4E 1270/4885TLR4 953/4885 |
| US-20230172956-A1 | COMBINATORIAL THERAPY FOR USE IN INDUCING IMMUNOGENIC CELL DEATH IN CANCER CELLS | HMGB1, CALR, HMGB2 | DHFR 1276/4885KDM4E 3973/4885TLR4 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.